RAISEing VEGF-D’s importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
RAISEing VEGF-D’s importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 29, Issue 3, Pages 527-529
Publisher
Oxford University Press (OUP)
Online
2018-01-18
DOI
10.1093/annonc/mdy028
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
- (2017) David Miles et al. EUROPEAN JOURNAL OF CANCER
- Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression
- (2016) R. Obermannová et al. ANNALS OF ONCOLOGY
- Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer
- (2016) Muhammad Wasif Saif et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D
- (2016) Natalia Davydova et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy
- (2016) Helena Verdaguer et al. Therapeutic Advances in Medical Oncology
- Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
- (2015) A J Weickhardt et al. BRITISH JOURNAL OF CANCER
- Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic
- (2015) Ace J. Hatch et al. CANCER JOURNAL
- Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
- (2015) Alexander Hein et al. INTERNATIONAL JOURNAL OF CANCER
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
- (2013) D W Miles et al. BRITISH JOURNAL OF CANCER
- Markers of Response for the Antiangiogenic Agent Bevacizumab
- (2013) Diether Lambrechts et al. JOURNAL OF CLINICAL ONCOLOGY
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
- (2012) Nicholas Papadopoulos et al. ANGIOGENESIS
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
- (2012) Diether Lambrechts et al. LANCET ONCOLOGY
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Structural determinants of vascular endothelial growth factor-D receptor binding and specificity
- (2010) V.-M. Leppanen et al. BLOOD
- VEGFs and receptors involved in angiogenesis versus lymphangiogenesis
- (2009) Marja Lohela et al. CURRENT OPINION IN CELL BIOLOGY
- Deletion of Vascular Endothelial Growth Factor C (VEGF-C) and VEGF-D Is Not Equivalent to VEGF Receptor 3 Deletion in Mouse Embryos
- (2008) P. Haiko et al. MOLECULAR AND CELLULAR BIOLOGY
- Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation
- (2008) Tuomas Tammela et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More